Compare KRMD & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | HBIO |
|---|---|---|
| Founded | 1980 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 26.5M |
| IPO Year | 2019 | 2000 |
| Metric | KRMD | HBIO |
|---|---|---|
| Price | $3.02 | $8.13 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 226.7K | 14.8K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $41,127,366.00 | ★ $116,176,000.00 |
| Revenue This Year | $16.78 | $3.76 |
| Revenue Next Year | $17.22 | $5.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.98 | $0.38 |
| 52 Week High | $6.61 | $8.40 |
| Indicator | KRMD | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 24.92 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $3.41 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 3.06 | 0.00 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.